Cutaneous Squamous Cell Carcinoma (cSCC) is a prevalent form of skin cancer. Neurotrophins and their receptors (CD271 and Trk) form a complex network regulating homeostasis of the epidermis, the site of cSCC. In this study, the authors showed that CD271 is upregulated in well-differentiated tumors as compared to the more aggressive moderately or poorly differentiated types of cSCC. CD271 overexpression and activation decrease cSCC cell invasiveness in vitro. Further, they observed a significant inhibition of the metastatic process modulated by CD271 in a newly established zebrafish cSCC model.

What is exciting about this article?

This report presents data supporting the role of the neurotrophin receptor CD271 in preventing the switch between low to high-risk cSCC tumors and suggests that it could be a promising target for future pharmaceutical development.

Grant support


Research Areas:

Cancer Biology Developmental Biology Genetics and Genomics Molecular Biology and Biochemistry Skin Biology


CD271 activation prevents low to high-risk progression of cutaneous squamous cell carcinoma and improves therapy outcomes.

Quadri M, Tiso N, Musmeci F, Morasso MI, Brooks SR, Bonetti LR, Panini R, Lotti R, Marconi A, Pincelli C, Palazzo E
J Exp Clin Cancer Res.
2023 Jul 13;
doi: 10.1186/s13046-023-02737-7
PMID: 37443031

Research reported in this publication was supported by the Intramural Research Program of the NIHʼs National Institute of Arthritis and Musculoskeletal and Skin Diseases.